Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 23174227)


Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology.

Spreafico F, Gamba B, Mariani L, Collini P, D'Angelo P, Pession A, Di Cataldo A, Indolfi P, Nantron M, Terenziani M, Morosi C, Radice P, Perotti D; AIEOP Wilms Tumor Working Group.

J Urol. 2013 Jan;189(1):260-6. doi: 10.1016/j.juro.2012.09.009. Epub 2012 Nov 20.


Loss of heterozygosity in a case of glomuvenous malformations.

Ohata C, Matsuda M, Hamada T, Shintani T, Muto I, Nagata H, Furumura M, Nakama T.

J Dermatol. 2015 Jun;42(6):646-7. doi: 10.1111/1346-8138.12849. Epub 2015 Mar 21. No abstract available.


Mixed fields on RhD typing as an indication of loss of heterozygosity on chromosome 1p in acute myeloid leukemia.

Chow S, Pendergrast J, Ochoa-Garay G, Gupta V, Munir ME, Craddock KJ, Wei C, Kamel-Reid S, Cserti-Gazdewich CM.

Leuk Lymphoma. 2015 Jan 14:1-4. [Epub ahead of print] No abstract available.


Risk stratification for wilms tumor: current approach and future directions.

Dome JS, Perlman EJ, Graf N.

Am Soc Clin Oncol Educ Book. 2014:215-23. doi: 10.14694/EdBook_AM.2014.34.215.


Gain of 1q is a marker of poor prognosis in Wilms' tumors.

Segers H, van den Heuvel-Eibrink MM, Williams RD, van Tinteren H, Vujanic G, Pieters R, Pritchard-Jones K, Bown N; Children's Cancer and Leukaemia Group and the UK Cancer Cytogenetics Group.

Genes Chromosomes Cancer. 2013 Nov;52(11):1065-74. doi: 10.1002/gcc.22101. Epub 2013 Sep 4.


Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.

Gratias EJ, Jennings LJ, Anderson JR, Dome JS, Grundy P, Perlman EJ.

Cancer. 2013 Nov 1;119(21):3887-94. doi: 10.1002/cncr.28239. Epub 2013 Aug 26.


Editorial comment.

Romao R, Lorenzo AJ.

J Urol. 2013 Jan;189(1):266; discussion 266-7. doi: 10.1016/j.juro.2012.09.175. Epub 2012 Nov 20. No abstract available.


Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor.

Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T, Okita H, Koshinaga T, Oue T, Hinotsu S, Nakadate H, Horie H, Fukuzawa M, Kaneko Y.

Pediatr Blood Cancer. 2012 Sep;59(3):499-505. doi: 10.1002/pbc.24093. Epub 2012 Mar 27.


Genomic profiling by whole-genome single nucleotide polymorphism arrays in Wilms tumor and association with relapse.

Perotti D, Spreafico F, Torri F, Gamba B, D'Adamo P, Pizzamiglio S, Terenziani M, Catania S, Collini P, Nantron M, Pession A, Bianchi M, Indolfi P, D'Angelo P, Fossati-Bellani F, Verderio P, Macciardi F, Radice P; Associazione Italiana Ematologia Oncologia Pediatrica Wilms Tumor Working Group.

Genes Chromosomes Cancer. 2012 Jul;51(7):644-53. doi: 10.1002/gcc.21951. Epub 2012 Mar 8.


Analysis of wilms tumors using SNP mapping array-based comparative genomic hybridization.

Hawthorn L, Cowell JK.

PLoS One. 2011 Apr 22;6(4):e18941. doi: 10.1371/journal.pone.0018941.


Loss of heterozygosity at chromosome 1p in human breast cancer.

Ragnarsson G, Sigurdsson A, Eiriksdottir G, Barkardottir R, Jonasson J, Ingvarsson S.

Int J Oncol. 1996 Oct;9(4):731-6.


Wilms tumors arising at young age: a genetic basis to distinguish subgroups for individualized therapy.

Royer-Pokora B, Graf N.

J Clin Oncol. 2011 Jun 1;29(16):e485-6; author reply e487-8. doi: 10.1200/JCO.2011.34.9209. Epub 2011 Apr 25. No abstract available.


Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

Spreafico F, Gandola L, D'Angelo P, Terenziani M, Collini P, Bianchi M, Provenzi M, Indolfi P, Pession A, Nantron M, Di Cataldo A, Marchianò A, Catania S, Fossati Bellani F, Piva L; AIEOP Wilms Tumor Working Group.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):348-54. doi: 10.1016/j.ijrobp.2010.09.022. Epub 2010 Nov 13.


Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?

Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F.

Neuro Oncol. 2010 May;12(5):490-9. doi: 10.1093/neuonc/nop071. Epub 2010 Feb 14.


1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis.

Durand KS, Guillaudeau A, Weinbreck N, DeArmas R, Robert S, Chaunavel A, Pommepuy I, Bourthoumieu S, Caire F, Sturtz FG, Labrousse FJ.

Mod Pathol. 2010 Apr;23(4):619-28. doi: 10.1038/modpathol.2009.185. Epub 2010 Jan 15.


Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features.

Sredni ST, Gadd S, Huang CC, Breslow N, Grundy P, Green DM, Dome JS, Shamberger RC, Beckwith JB, Perlman EJ; Renal Tumor Committee of the Children's Oncology Group.

Clin Cancer Res. 2009 Nov 15;15(22):6800-9. doi: 10.1158/1078-0432.CCR-09-0312. Epub 2009 Nov 10.


Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.

Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, Jones C, Aldred MA.

Clin Cancer Res. 2009 Oct 1;15(19):5985-92. doi: 10.1158/1078-0432.CCR-09-1065. Epub 2009 Sep 29.


Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.

Ohshima J, Haruta M, Arai Y, Kasai F, Fujiwara Y, Ariga T, Okita H, Fukuzawa M, Hata J, Horie H, Kaneko Y.

Genes Chromosomes Cancer. 2009 Dec;48(12):1037-50. doi: 10.1002/gcc.20705.


Surgical aspects in the treatment of patients with unilateral wilms tumor: a report from the SIOP 93-01/German Society of Pediatric Oncology and Hematology.

Fuchs J, Kienecker K, Furtwängler R, Warmann SW, Bürger D, Thürhoff JW, Hager J, Graf N.

Ann Surg. 2009 Apr;249(4):666-71. doi: 10.1097/SLA.0b013e31819ed92b.


Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study.

Messahel B, Williams R, Ridolfi A, A'hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanic G, Pritchard-Jones K; Children's Cancer and Leukaemia Group (CCLG).

Eur J Cancer. 2009 Mar;45(5):819-26. doi: 10.1016/j.ejca.2009.01.005. Epub 2009 Feb 21.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk